Tolerability and outcome of PINPOINT therapy
| Table 1 | Group A | Group B |
| Mean Age | 64 | 61 |
| Sex ratio (M:F) | 14:16 | 6:18 |
| Mean baseline SpO2 (%) | 95 | 93 |
| Mean FEV1 (L) | 1.44 | 1.21 |
| Mean FVC (L) | 1.56 | 1.32 |
| Home O2 | 6 | 5 |
| Home BiPAP | 1 | 2 |
| Mean Pirfenidone dose (mg/kg/day) | 17 | 18 |
| Mean absolute Pirfenidone dose (mg/day) | 1009 | 950 |
| Adverse reactions | 6 | 5 |
| Stop Pirfenidone | 6 | 4 |
| Acute Exacerbation | 5 | 6 |
| Death | 4 | 6 |
| Median duration from start of Symptoms to PINPOINT (months) | 3 (1-60) | 13 (3 -61) |
| Median duration from start of PINPOINT to last follow up/ stop Pirfenidone/ Death | 9 (1-21) | 10 (1-22) |